XNCR

In the past six months, Xencor's stock (XNCR) has experienced significant upward momentum, increasing by 107.42%, with a 61.3% rise year-to-date as of September 23, 2026, and a 185.23% increase over the last 12 months. Key events impacting the stock price include Xencor reporting Q2 2026 earnings that beat analysts' consensus estimates for earnings per share on August 5, 2026. The company presented at the 2026 Cantor Global Healthcare Conference on September 9, 2026, and is scheduled to present again on September 23, 2026, where it highlighted a strategic shift from a platform licensing business to a late-stage drug developer with upcoming data events for its XmAb819 and XmAb541 programs. Additionally, Xencor is set to receive $105 million from Alexion to resolve a U.S. royalty matter related to Ultomiris, and BofA raised its price target on Xencor (XNCR) to $26 from $20, maintaining a Neutral rating.